HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline With Two Lead Immuno-Oncology Programs and Validate Its DIS™ Approach in the Clinic

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3iDDKfm
via IFTTT